Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06263543 · ClinicalTrials.gov registry record · Phase 2
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
A Phase 2 study of Breast Cancer and Metastatic Breast Cancer, sponsored by Reshma L. Mahtani, D.O..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 3
- Study locations
NCT06263543: Recruiting Phase 2 study of Breast Cancer and Metastatic Breast Cancer, sponsored by Reshma L. Mahtani, D.O..
NCT06263543 is a Phase 2 study of Breast Cancer and Metastatic Breast Cancer that is actively recruiting participants, run by Reshma L. Mahtani, D.O.. The registered enrollment target is 75 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06263543, a Phase 2 study of Breast Cancer and Metastatic Breast Cancer, is actively recruiting participants, sponsored by Reshma L. Mahtani, D.O..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this research study is to see if the medication sacituzumab govitecan (SG) is effective at the currently approved dose and schedule in people who have previously received trastuzumab deruxtecan (T-DXd) for the treatment of metastatic, hormone receptor positive (HR+)/human epidermal growth factor 2 low (HER2 low) breast cancer. Although SG is approved to treat metastatic HR+/HER2 negative breast cancer, the aim of this study is to determine if SG is still effective specifically in people who have already received T-DXd.
Primary Outcome
ORR will be assessed using Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1). ORR is defined as the percentage of participants who received at least one dose of SG and have achieved a complete response (CR) or partial response (PR) as assessed by the local investigator.
Conditions Studied
Interventions
- DRUG Sacituzumab govitecan
Study Locations (3)
California
- UCLA Jonsson Comprehensive Cancer Center - Los Angeles
Florida
- Miami Cancer Institute at Baptist Health, Inc. - Miami
Georgia
- Winship Cancer Institute at Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2024-06-17 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What NCT06263543 shows while recruiting
NCT06263543 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower).
The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Sacituzumab govitecan is the first listed.
NCT06263543 reports a single indexed study location in California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06263543 about?
NCT06263543 is a clinical study titled "Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC". The purpose of this research study is to see if the medication sacituzumab govitecan (SG) is effective at the currently approved dose and schedule in people who have previously received trastuzumab deruxtecan (T-DXd) for the treatment of metastatic, hormone receptor positive (HR+)/human epidermal gr...
What is the current status of trial NCT06263543?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2024-06-17. Estimated completion is 2026-12.
What conditions does trial NCT06263543 study?
This clinical trial studies the following conditions: Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Hormone Receptor-Positive Breast Cancer, Human Epidermal Growth Factor 2 Low Breast Cancer.
What interventions are being tested in trial NCT06263543?
The interventions under investigation include: Sacituzumab govitecan (DRUG).
Who is sponsoring clinical trial NCT06263543?
This trial is sponsored by Reshma L. Mahtani, D.O., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06263543 being conducted?
This trial has 3 study locations across California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06263543's enrollment target sits among peer trials
75 675th of 1224 higher than 544 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
-
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI